Synexo Group (SYNEXO) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
Net sales for Q1–Q3 2024 were SEK 9.6m, down 45% year-over-year; operating loss widened to SEK -9.7m from SEK -7.5m.
Market conditions, including the Hollywood strike and macroeconomic headwinds, significantly impacted customer demand and industry sales.
LC-Tec launched the world's first electronic variable diffusion filter (EVD) for cine lenses and received industry awards at IBC 2024.
The company expects sales for 2024 to be significantly below expectations, with recovery now anticipated in 2025/2026.
Cost-saving measures and a review of operations have been initiated; recapitalization proposal in progress.
Financial highlights
Net sales Q3 2024: SEK 2.4m (Q3 2023: SEK 4.7m); Q1–Q3 2024: SEK 9.6m (Q1–Q3 2023: SEK 17.6m).
Operating result Q3 2024: SEK -3.9m (Q3 2023: SEK -2.0m); Q1–Q3 2024: SEK -9.7m (Q1–Q3 2023: SEK -7.5m).
Net result Q1–Q3 2024: SEK -10.2m (Q1–Q3 2023: SEK -8.0m); EPS: SEK -0.16 (Q1–Q3 2023: SEK -0.27).
Cash flow from operations Q1–Q3 2024: SEK -12.5m (Q1–Q3 2023: SEK -7.2m); cash at period end: SEK 2.3m.
Equity at period end: SEK 6.0m; equity ratio: 46%.
Outlook and guidance
Sales for 2024 expected to be significantly lower than company and market expectations.
Recovery in sales now anticipated for 2025/2026; losses expected to continue until then.
No formal forecast provided for coming periods.
Latest events from Synexo Group
- ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 202528 Nov 2025 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 202521 Aug 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 20256 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025